Premium
Linezolid‐ and vancomycin‐resistant Enterococcus faecium endocarditis: Successful treatment with tigecycline and daptomycin
Author(s) -
Jenkins Ian
Publication year - 2007
Publication title -
journal of hospital medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.128
H-Index - 65
eISSN - 1553-5606
pISSN - 1553-5592
DOI - 10.1002/jhm.236
Subject(s) - daptomycin , tigecycline , medicine , linezolid , enterococcus faecium , vancomycin , endocarditis , enterococcus , vancomycin resistant enterococcus , gram positive bacterial infections , microbiology and biotechnology , antibiotics , staphylococcus aureus , bacteria , biology , genetics
University of Calfornia, San Diego Enterococci are a leading cause of endocarditis and nosocomial infections. Vancomycin-resistant enterococci (VRE) emerged in the 1980s and now represent most nosocomial isolates in the United States. The first case of VRE endocarditis was reported in 1996. Although increasing enterococcal antibiotic resistance has prompted increasing reliance on newer antibiotics, a recent review of VRE endocarditis noted that survival rates were similar to those for vancomycin-sensitive enterococcal endocarditis. Cure was achieved in several patients with bacteriostatic agents in the absence of valve replacement, but no patients were infected with truly linezolid-resistant organisms. This case of linezolid-resistant VRE endocarditis represents the first reported cure of infective endocarditis with a tigecycline-containing regimen.